Purity determinations in the bulk drug of the novel indoloquinone antitumor agent EO9.
The pharmaceutical development of the investigational cytotoxic drug EO9 included the structural characterization of the bulk drug by nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS) and infrared (IR) spectroscopy, and analytical characterization by high-performance liquid chromatography and ultraviolet/visible spectrophotometry. The presence of impurities in the bulk drug was investigated. The intermediates in the synthesis of EO9 were structurally characterized by NMR spectroscopy and MS, and analytically characterized by HPLC analysis with photodiode array (PDA) detection. All of the intermediates were below their limits of detection in EO9 bulk drug. The amounts of residual organic solvents were determined by gas chromatography. Methanol and ethanol were detected, but the amounts present did not exceed the limits as set in the United States Pharmacopeia XXII.
Department of Pharmacy, Slotervaart Hospital/Netherlands Cancer Institute, Amsterdam, The Netherlands.
J D
JD
Jonkman-de Vries
J J
JJ
Kettenes-van den Bosch
R E
RE
Henrar
A
A
Bult
J H
JH
Beijnen
D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000302:isolation & purification*; D001388:Aziridines / Q000138:chemical synthesis / Q000302:isolation & purification*; D002626:Chemistry, Pharmaceutical / Q000379:methods / Q000592:standards; D045563:Indolequinones; D007211:Indoles / Q000138:chemical synthesis / Q000302:isolation & purification*; D009682:Magnetic Resonance Spectroscopy; D013058:Mass Spectrometry; D011786:Quality Control; D013056:Spectrophotometry, Ultraviolet
D000970:Antineoplastic Agents; D001388:Aziridines; D045563:Indolequinones; D007211:Indoles; C060817:apaziquone